{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:50:32Z","timestamp":1778759432670,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["MMA 2013\/0069"],"award-info":[{"award-number":["MMA 2013\/0069"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12943-017-0618-7","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T08:45:26Z","timestamp":1487839526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin"],"prefix":"10.1186","volume":"16","author":[{"given":"Alba","family":"Agudo-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Prieto-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Vanesa","family":"D\u00edaz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Parrilla-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Navarro-Ranninger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hern\u00e1n","family":"Cort\u00e9s-Funes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 A.","family":"L\u00f3pez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Teresa","family":"Agull\u00f3-Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"issue":"47","key":"618_CR1","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379.","journal-title":"Oncogene"},{"issue":"15","key":"618_CR2","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"1","key":"618_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/jm100020w","volume":"54","author":"G Gasser","year":"2010","unstructured":"Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. J Med Chem. 2010;54(1):3\u201325.","journal-title":"J Med Chem"},{"issue":"2","key":"618_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088193","volume":"9","author":"C Federici","year":"2014","unstructured":"Federici C, Petrucci F, Caimi S, Cesolini A, Logozzi M, Borghi M, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One. 2014;9(2), e88193.","journal-title":"PLoS One"},{"issue":"6","key":"618_CR5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-016-2976-z","volume":"77","author":"S Dilruba","year":"2016","unstructured":"Dilruba S, Kalayda GV. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2016;77(6):1103\u201324.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"618_CR6","doi-asserted-by":"crossref","first-page":"12627","DOI":"10.1021\/ic502373n","volume":"53","author":"JM Herrera","year":"2014","unstructured":"Herrera JM, Mendes F, Gama S, Santos I, Navarro Ranninger C, Cabrera S, et al. Design and biological evaluation of new platinum(II) complexes bearing ligands with DNA-targeting ability. Inorg Chem. 2014;53(23):12627\u201334.","journal-title":"Inorg Chem"},{"key":"618_CR7","doi-asserted-by":"crossref","unstructured":"Cetraz M, Sen V, Schoch S, Streule K, Golubev V, Hartwig A, et al. Platinum(IV)-nitroxyl complexes as possible candidates to circumvent cisplatin resistance in RT112 bladder cancer cells. Arch Toxicol. 2017;91(2):785\u201397.","DOI":"10.1007\/s00204-016-1754-3"},{"issue":"29","key":"618_CR8","doi-asserted-by":"crossref","first-page":"11830","DOI":"10.1039\/C6DT02207C","volume":"45","author":"J Ma","year":"2016","unstructured":"Ma J, Wang Q, Yang X, Hao W, Huang Z, Zhang J, et al. Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects. Dalton Trans. 2016;45(29):11830\u20138.","journal-title":"Dalton Trans"},{"issue":"23","key":"618_CR9","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/jm061076u","volume":"49","author":"JY Chang","year":"2006","unstructured":"Chang JY, Hsieh HP, Chang CY, Hsu KS, Chiang YF, Chen CM, et al. 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. J Med Chem. 2006;49(23):6656\u20139.","journal-title":"J Med Chem"},{"issue":"4","key":"618_CR10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/cmdc.201100529","volume":"7","author":"Z Liu","year":"2012","unstructured":"Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, et al. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities. ChemMedChem. 2012;7(4):680\u201393.","journal-title":"ChemMedChem"},{"key":"618_CR11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jinorgbio.2013.01.013","volume":"127","author":"V Solar Del","year":"2013","unstructured":"Del Solar V, Quinones-Lombrana A, Cabrera S, Padron JM, Rios-Luci C, Alvarez-Valdes A, et al. Expanding the synthesis of new trans-sulfonamide platinum complexes: cytotoxicity, SAR, fluorescent cell assays and stability studies. J Inorg Biochem. 2013;127:128\u201340.","journal-title":"J Inorg Biochem"},{"issue":"19","key":"618_CR12","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.2174\/092986709788682083","volume":"16","author":"G Cossa","year":"2009","unstructured":"Cossa G, Gatti L, Zunino F, Perego P. Strategies to improve the efficacy of platinum compounds. Curr Med Chem. 2009;16(19):2355\u201365.","journal-title":"Curr Med Chem"},{"issue":"9","key":"618_CR13","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/1535-7163.MCT-11-0250","volume":"10","author":"KS Lovejoy","year":"2011","unstructured":"Lovejoy KS, Serova M, Bieche I, Emami S, D\u2019Incalci M, Broggini M, et al. Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther. 2011;10(9):1709\u201319.","journal-title":"Mol Cancer Ther"},{"key":"618_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ejmech.2014.02.022","volume":"76","author":"C Perez","year":"2014","unstructured":"Perez C, Diaz-Garcia CV, Agudo-Lopez A, Del Solar V, Cabrera S, Agullo-Ortuno MT, et al. Evaluation of novel trans-sulfonamide platinum complexes against tumor cell lines. Eur J Med Chem. 2014;76:360\u20138. doi: 10.1016\/j.ejmech.2014.02.022 .","journal-title":"Eur J Med Chem"},{"issue":"50","key":"618_CR15","doi-asserted-by":"crossref","first-page":"20373","DOI":"10.1073\/pnas.1218938109","volume":"109","author":"LC Godoy","year":"2012","unstructured":"Godoy LC, Anderson CT, Chowdhury R, Trudel LJ, Wogan GN. Endogenously produced nitric oxide mitigates sensitivity of melanoma cells to cisplatin. Proc Natl Acad Sci U S A. 2012;109(50):20373\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"618_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000062","volume":"24","author":"A Alrwas","year":"2014","unstructured":"Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, et al. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-alpha in patients with metastatic melanoma. Melanoma Res. 2014;24(4):342\u20138.","journal-title":"Melanoma Res"},{"issue":"19","key":"618_CR17","first-page":"4285","volume":"57","author":"PM O\u2019Connor","year":"1997","unstructured":"O\u2019Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57(19):4285\u2013300.","journal-title":"Cancer Res"},{"issue":"8","key":"618_CR18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bcp.2011.12.026","volume":"83","author":"M Martinez-Rivera","year":"2012","unstructured":"Martinez-Rivera M, Siddik ZH. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem Pharmacol. 2012;83(8):1049\u201362.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"618_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"618_CR20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2011.04.034","volume":"122","author":"G He","year":"2011","unstructured":"He G, Kuang J, Khokhar AR, Siddik ZH. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog. Gynecol Oncol. 2011;122(2):402\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"618_CR21","first-page":"119","volume":"28","author":"CM Park","year":"2006","unstructured":"Park CM, Park MJ, Kwak HJ, Moon SI, Yoo DH, Lee HC, et al. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol. 2006;28(1):119\u201325.","journal-title":"Int J Oncol"},{"issue":"1","key":"618_CR22","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"AM Florea","year":"2011","unstructured":"Florea AM, Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351\u201371.","journal-title":"Cancers"},{"issue":"4","key":"618_CR23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.coph.2005.04.009","volume":"5","author":"I Collins","year":"2005","unstructured":"Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol. 2005;5(4):366\u201373.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"618_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.devcel.2008.01.013","volume":"14","author":"A Besson","year":"2008","unstructured":"Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14(2):159\u201369.","journal-title":"Dev Cell"},{"issue":"8","key":"618_CR25","first-page":"639","volume":"1","author":"AL Gartel","year":"2002","unstructured":"Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1(8):639\u201349.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"618_CR26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/1947601911432495","volume":"2","author":"LA Hoeferlin","year":"2011","unstructured":"Hoeferlin LA, Oleinik NV, Krupenko NI, Krupenko SA. Activation of p21-Dependent G1\/G2 arrest in the absence of DNA damage as an antiapoptotic response to metabolic stress. Genes Cancer. 2011;2(9):889\u201399.","journal-title":"Genes Cancer"},{"issue":"5","key":"618_CR27","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ccr.2013.03.013","volume":"23","author":"M Lu","year":"2013","unstructured":"Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1\/CDK1-phosphorylated nuclear iASPP. Cancer Cell. 2013;23(5):618\u201333.","journal-title":"Cancer Cell"},{"issue":"1","key":"618_CR28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/138955712798868940","volume":"12","author":"A Lavecchia","year":"2012","unstructured":"Lavecchia A, Di Giovanni C, Novellino E. CDC25 phosphatase inhibitors: an update. Mini Rev Med Chem. 2012;12(1):62\u201373.","journal-title":"Mini Rev Med Chem"},{"issue":"6","key":"618_CR29","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1134\/S000629791206003X","volume":"77","author":"VS Romanov","year":"2012","unstructured":"Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry (Mosc). 2012;77(6):575\u201384.","journal-title":"Biochemistry (Mosc)"},{"issue":"6","key":"618_CR30","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9(6):400\u201314.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"618_CR31","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0962-8924(02)00043-0","volume":"13","author":"O Coqueret","year":"2003","unstructured":"Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003;13(2):65\u201370.","journal-title":"Trends Cell Biol"},{"issue":"6","key":"618_CR32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1600-0854.2010.01063.x","volume":"11","author":"N Abella","year":"2010","unstructured":"Abella N, Brun S, Calvo M, Tapia O, Weber JD, Berciano MT, et al. Nucleolar disruption ensures nuclear accumulation of p21 upon DNA damage. Traffic. 2010;11(6):743\u201355.","journal-title":"Traffic"},{"issue":"5","key":"618_CR33","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/emboj\/18.5.1223","volume":"18","author":"M Asada","year":"1999","unstructured":"Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1\/WAF1) in monocytic differentiation. Embo J. 1999;18(5):1223\u201334.","journal-title":"Embo J"},{"issue":"8","key":"618_CR34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/sj.onc.1202021","volume":"17","author":"A Suzuki","year":"1998","unstructured":"Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene. 1998;17(8):931\u20139.","journal-title":"Oncogene"},{"issue":"6","key":"618_CR35","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1046\/j.1523-1747.1999.00812.x","volume":"113","author":"ES Bales","year":"1999","unstructured":"Bales ES, Dietrich C, Bandyopadhyay D, Schwahn DJ, Xu W, Didenko V, et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol. 1999;113(6):1039\u201346.","journal-title":"J Invest Dermatol"},{"issue":"11","key":"618_CR36","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/1078-0432.CCR-03-0527","volume":"10","author":"W Xia","year":"2004","unstructured":"Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, et al. Phosphorylation\/cytoplasmic localization of p21Cip1\/WAF1 is associated with HER2\/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 2004;10(11):3815\u201324.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"618_CR37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","volume":"183","author":"J Slingerland","year":"2000","unstructured":"Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183(1):10\u20137.","journal-title":"J Cell Physiol"},{"issue":"6","key":"618_CR38","doi-asserted-by":"crossref","first-page":"R242","DOI":"10.1186\/bcr654","volume":"5","author":"ZE Winters","year":"2003","unstructured":"Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL. Cytoplasmic p21WAF1\/CIP1 expression is correlated with HER-2\/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003;5(6):R242\u20139.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"618_CR39","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI41939","volume":"120","author":"R Koster","year":"2010","unstructured":"Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, et al. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010;120(10):3594\u2013605.","journal-title":"J Clin Invest"},{"key":"618_CR40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/1471-2407-11-399","volume":"11","author":"X Xia","year":"2011","unstructured":"Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, et al. Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer. BMC Cancer. 2011;11:399.","journal-title":"BMC Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-017-0618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:12:50Z","timestamp":1498374770000},"score":1,"resource":{"primary":{"URL":"http:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-017-0618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["618"],"URL":"https:\/\/doi.org\/10.1186\/s12943-017-0618-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]},"article-number":"45"}}